Large, but non-randomised, series suggest that anti-EGFR monoclonal antibodies are inactive in BRAF-mutated cancers;14, 15, 17 however, retrospective analysis of BRAF status in two randomised trials, although showing a low response rate in patients with BRAF mutations, showed no evidence of a negative interaction on PFS.2 The gene discussed is BRAF; the disease is cancer.